Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2023) 94 P184 | DOI: 10.1530/endoabs.94.P184

SFEBES2023 Poster Presentations Adrenal and Cardiovascular (78 abstracts)

Prednisolone replacement therapy is associated with significant weight loss in patients who switch from hydrocortisone with adrenal insufficiency

Katharine Lazarus 1,2 , Sirazum Choudhury 1,2,3 , Kavita Narula 1,2 , Deborah Papadopoulou 2 , Tricia Tan 1,2,3 & Karim Meeran 1,2


1Division of Diabetes, Endocrinology and Metabolism, Department of Metabolism, Digestion and Reproduction, Imperial College London, London, United Kingdom. 2Department of Endocrinology, Imperial College Healthcare NHS Trust, London, United Kingdom. 3Department of Clinical Biochemistry, Northwest London Pathology, London, United Kingdom


Background: Adrenal Insufficiency (AI) is a life-threatening disorder caused by dysfunction of the adrenal axis (primary AI) or of the hypothalamic-pituitary-adrenal axis (secondary AI). Both result in glucocorticoid deficiency, requiring life-long replacement, with additional mineralocorticoid replacement required in primary AI. However, accurately reproducing the endogenous circadian and ultradian rhythm of cortisol secretion is challenging. Current Endocrine Society guidelines recommend either hydrocortisone (thrice-daily) or once-daily prednisolone (3-5mg). Concerns around adverse metabolic outcomes associated with prednisolone have been based on evidence using higher prednisolone doses. We have used low-dose (2-4mg) prednisolone once-daily since 2014 for glucocorticoid replacement in adults with AI. Since 2018 we have prospectively audited patients switched from hydrocortisone to prednisolone, and from prednisolone to hydrocortisone (HYPER-AID study (NCT03608943)).

Methods: Patients were clinically followed up at for least 4 months following the switch prior to repeat measurements being taken. Data was analysed using Microsoft Excel and GraphPad Prism version 9.3.1 (GraphPad, San Diego, CA,). Significance was assessed using paired t-tests, with significance defined at P<0.05.

Results: Of the 23 patients who have completed both visits, 12 switched from hydrocortisone to prednisolone, and 11 from prednisolone to hydrocortisone. The mean weights of patients on hydrocortisone and prednisolone were 80.2kg and 77.7kg respectively, with a difference of 2.6kg (P<0.01). In those who switched from prednisolone to hydrocortisone, there was a significant weight gain of 3.2kg (P<0.004).

Discussion: The mechanism of the weight loss found with prednisolone may be due to overall less glucocorticoid exposure or because it mimics a more physiological circadian profile, avoiding supraphysiological cortisol levels later in the day. Once-daily low-dose prednisolone in the treatment of adrenal insufficiency is safe. Preliminary results of the HYPER-AID study suggest that prednisolone may have a beneficial effect on weight in those who are switched from hydrocortisone.

Volume 94

Society for Endocrinology BES 2023

Glasgow, UK
13 Nov 2023 - 15 Nov 2023

Society for Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.